Efficiency of Human Olfactory Ensheathing Cell Transplantation into Spinal Cysts to Improve Mobility of the Hind Limbs

Степанова, О. В.; Воронова, А Д; Чадин, А. В.; Valikhov, Marat P.; Semkina, Alevtina S.; Karsuntseva, E. K.; Chekhonin, Ivan V.; Shishkina, V. S.; Reshetov, Igor V.; Чехонин, В. П.

doi:10.1089/scd.2019.0092

Cited by 14 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long-term cell survival (8–11 weeks) was also observed upon NSPC implantation ( Ziv et al, 2006 ; Biernaskie et al, 2007 ; Hwang et al, 2019 ), and transduction of NSPCs by rAdVs did not change the duration of cell survival after implantation ( Biernaskie et al, 2007 ; Hwang et al, 2019 ). Long-term survival (spanning several months) has also been shown for OECs used for SCI therapy ( Ruitenberg et al, 2002 , 2003 ; Mayeur et al, 2013 ; Stepanova et al, 2019 ). rAdV-mediated expression of a transgene also did not decrease OEC survival after implantation, but transgene expression gradually decreased between the 7th and 30th days after implantation ( Ruitenberg et al, 2002 ).…”

Section: The Immune Response To Recombinant Adenoviruses In the Context Of Sci Therapymentioning

confidence: 94%

“…Olfactory ensheathing cells (OECs) have also demonstrated success in the therapy of experimental SCI ( Mayeur et al, 2013 ; Stepanova et al, 2019 ). OECs were susceptible to infection with rAdV5, reaching 100% transduction efficiency at an MOI of 100 without observable changes in their cellular phenotype or expression of cell markers.…”

Section: The Transduction Efficiency Of Recombinant Adenovirusesmentioning

confidence: 99%

See 1 more Smart Citation

Recombinant Adenoviruses for Delivery of Therapeutics Following Spinal Cord Injury

et al. 2022

Self Cite

View full text Add to dashboard Cite

The regeneration of nerve tissue after spinal cord injury is a complex and poorly understood process. Medication and surgery are not very effective treatments for patients with spinal cord injuries. Gene therapy is a popular approach for the treatment of such patients. The delivery of therapeutic genes is carried out in a variety of ways, such as direct injection of therapeutic vectors at the site of injury, retrograde delivery of vectors, and ex vivo therapy using various cells. Recombinant adenoviruses are often used as vectors for gene transfer. This review discusses the advantages, limitations and prospects of adenovectors in spinal cord injury therapy.

show abstract

Section: The Immune Response To Recombinant Adenoviruses In the Context Of Sci Therapymentioning

confidence: 94%

Section: The Transduction Efficiency Of Recombinant Adenovirusesmentioning

confidence: 99%

Recombinant Adenoviruses for Delivery of Therapeutics Following Spinal Cord Injury

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The BBB scale of rats was evaluated before operation, at 3 hours, and every 4 days afterward until 4 weeks after successful modeling to assess the locomotion function recovery of the hind limbs [ 13 ]. The scores on the BBB scale increase as the ability to perform fine hind limb movements improves.…”

Section: Methodsmentioning

confidence: 99%

“…Therefore, we first applied hematoxylin and eosin (H&E) staining to the damaged section of the spinal cord in a cross manner to verify the angiogenesis and neural restoration effect of TCH injection. Subsequently, we tested the recovery of the motor function of rats by applying the Basso, Beattie, and Bresnahan (BBB) scale [ 13 ]. RNA-seq provides the transcriptomic characterization of an individual's activity in a spatiotemporal-specific manner; thus, we did a transcriptome analysis on the rats that were treated with TCH injection after SCI.…”

Section: Introductionmentioning

confidence: 99%

Transcriptome Analysis Reveals the Effects of Troxerutin and Cerebroprotein Hydrolysate Injection on Injured Spinal Cords in Rats

Wang

Tang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Spinal cord injury (SCI) is a serious condition that results in disability and has a high morbidity rate; its treatment is very difficult. Although troxerutin and cerebroprotein hydrolysate (TCH) injections have been extensively used in clinics in China for the treatment of traumatic brain injury (TBI) and cerebral stroke, the potential efficacy of TCH injection in the treatment of SCI has never been revealed. In this study, the effects of administering TCH injections on neurological recovery in post-SCI rats were first tested with regard to the behavior and histology; subsequently, the specific expression profile of mRNAs and long noncoding RNAs (LncRNAs) in their spinal cords were conducted using RNA sequencing (RNA-seq). The LncRNA-mRNA networks were also elucidated. After SCI, we found that TCH injection with the right dose is effective for the recovery of locomotion function and repairing of the damaged tissue in the spinal cord; TCH injection is also discovered to have a role in the regulation of 443 differentially expressed genes (DEGs) and 27 differentially expressed LncRNAs (DELs) that are identified to have multiple functions, including locomotion, blood vessel morphogenesis, thiamine metabolism, Hippo signaling pathway, and axon guidance, by applying the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) analysis. In addition, it is revealed that, after SCI, the highly expressed LncRNA AABR07071383.1 in the post-SCI cis/trans-regulates the expression of mRNA Acpp mRNA that encodes a key enzyme involved in the metabolic process of thiamine in the abirritation of the dorsal root ganglion (DRG), which implies that TCH injection may be more effective when administered with benfotiamine (a common treatment drug).

show abstract

“…Primary human embryonic dermal fibroblasts and embryonic astrocytes (a cell bank of V.P. Serbsky National Medical Research Center, Moscow, Russia), and primary OECs 68 were cultured in DMEM/F12 (Gibco) with 10% FBS. T/G HA-VSMCs (CRL-1999, ATCC) were cultured in F-12K medium (Gibco) with 2 mM L-glutamine; 1,500 mg/L sodium bicarbonate; 0.05 mg/mL ascorbic acid (Sigma); 0.01 mg/mL insulin (Gibco); 0.01 mg/mL transferrin (Gibco); 10 ng/mL sodium selenite (Gibco); 0.03 mg/mL endothelial cell growth supplement (ECGS, Sigma); HEPES (10 mM); TES (10 mM, Sigma); 10% FBS; and 25 mg/mL amphotericin B (Gibco).…”

Section: Cell Linesmentioning

confidence: 99%

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures

Stepanenko

Сосновцева

Valikhov

et al. 2022

Molecular Therapy - Oncolytics

Self Cite

View full text Add to dashboard Cite

Ad5-delta-24-RGD is currently the most clinically advanced recombinant adenovirus (rAd) for glioma therapy. We constructed a panel of fiber-modified rAds (Ad5RGD, Ad5/3, Ad5/35, Ad5/3RGD, and Ad5/35RGD, all harboring the delta-24 modification) and compared their infectivity, replication, reproduction, and cytolytic efficacy in human and rodent glioma cell lines and short-term cultures from primary gliomas. In human cells, both Ad5/35-delta-24 and Ad5/3-delta-24 displayed superior infectivity and cytolytic efficacy over Ad5-delta-24-RGD, while Ad5/3-delta-24-RGD and Ad5/35delta-24-RGD did not show further improvements in efficacy. The expression of the adenoviral receptors/coreceptors CAR, DSG2, and CD46 and the integrins aVb3/aVb5 did not predict the relative cytolytic efficacy of the fiber-modified rAds. The cytotoxicity of the fiber-modified rAds in human primary normal cultures of different origins and in primary glioma cultures was comparable, indicating that the delta-24 modification did not confer tumor cell selectivity. We also revealed that CT-2A and GL261 glioma cells might be used as murine cell models for the fiber chimeric rAds in vitro and in vivo. In GL261 tumor-bearing mice, Ad5/35-delta-24, armed with the immune costimulator OX40L as the E2A/DBP-p2A-mOX40L fusion, produced long-term survivors, which were able to reject tumor cells upon rechallenge. Our data underscore the potential of local Ad5/35-delta-24-based immunovirotherapy for glioblastoma treatment.

show abstract

Efficiency of Human Olfactory Ensheathing Cell Transplantation into Spinal Cysts to Improve Mobility of the Hind Limbs

Cited by 14 publications

References 46 publications

Recombinant Adenoviruses for Delivery of Therapeutics Following Spinal Cord Injury

Recombinant Adenoviruses for Delivery of Therapeutics Following Spinal Cord Injury

Transcriptome Analysis Reveals the Effects of Troxerutin and Cerebroprotein Hydrolysate Injection on Injured Spinal Cords in Rats

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures

Contact Info

Product

Resources

About